公开(公告)号：US20110245200A1

公开(公告)日：2011-10-06

申请号：US13003623

申请日：2009-07-17

申请人： Roger Cariou ,  Paul Chew ,  Jean-Michel Destors ,  Gérard Pillion ,  Louise Silvestre

发明人： Roger Cariou ,  Paul Chew ,  Jean-Michel Destors ,  Gérard Pillion ,  Louise Silvestre

IPC分类号： A61K31/702 ,  A61P9/14 ,  A61P7/02

CPC分类号： A61K31/7056

摘要： The invention relates to the use of idrabiotaparinux for the treatment and secondary prevention of thrombotic pathologies, wherein the use of idrabiotaparinux involves a decrease in the incidence of bleedings, in particular major bleedings, during said treatment.

摘要翻译： 本发明涉及idrabiotiotarinux用于治疗和二次预防血栓形成病理学的用途，其中在所述治疗期间使用异iot iot素涉及出血发生率的降低，特别是主要出血。

公开(公告)号：US20060122151A1

公开(公告)日：2006-06-08

申请号：US11269893

申请日：2005-11-09

申请人： Roger Cariou

发明人： Roger Cariou

IPC分类号： A61K31/737 ,  A61K31/60

CPC分类号： A61K45/06 ,  A61K31/60 ,  A61K31/616 ,  A61K31/737 ,  A61K2300/00

摘要： The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty. The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.

摘要翻译： 本发明涉及合成寡糖，其是通过单独或与阿司匹林联合的抗凝血酶III作用的因子Xa的选择性抑制剂，用于制备用于预防或治疗发生在已经经历过的哺乳动物中的血栓栓塞性疾病的药物 经皮腔内血管成形术。 本发明的主题是用于治疗或预防已经经历经皮腔内血管成形术的哺乳动物中的血栓栓塞性疾病的药物组合物，其包含有效量的至少一种合成寡糖的缔合，所述合成寡糖是选择性因子因子 Xa通过抗凝血酶III起作用，并且有效量的阿斯匹林，任选地与一种或多种药学上可接受的赋形剂混合。